Current Opinion in Urology最新文献_第4页

Biochemical recurrence in prostate cancer - toward precision in definition, diagnosis, and management. 前列腺癌生化复发的精确定义、诊断和治疗。

IF 2.2 3区医学

Current Opinion in Urology Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI: 10.1097/MOU.0000000000001316

Tobias Maurer, Fabian Falkenbach

引用次数: 0

Carbon ion radiotherapy as a dose escalation tool in the treatment of primary high-risk prostate cancer. 碳离子放疗作为一种剂量递增治疗原发性高危前列腺癌的工具。

IF 2.2 3区医学

Current Opinion in Urology Pub Date : 2025-09-01 Epub Date: 2025-07-17 DOI: 10.1097/MOU.0000000000001327

Matthias Moll, Piero Fossati, Carola Lütgendorf-Caucig, Eugen Hug

引用次数: 0

Recent advancements in personalized management of prostate cancer biochemical recurrence after radical prostatectomy. 根治性前列腺切除术后前列腺癌生化复发的个体化治疗进展。

IF 2.2 3区医学

Current Opinion in Urology Pub Date : 2025-09-01 Epub Date: 2025-05-14 DOI: 10.1097/MOU.0000000000001305

Fabian Falkenbach, Jonas Ekrutt, Tobias Maurer

{"title":"Recent advancements in personalized management of prostate cancer biochemical recurrence after radical prostatectomy.","authors":"Fabian Falkenbach, Jonas Ekrutt, Tobias Maurer","doi":"10.1097/MOU.0000000000001305","DOIUrl":"10.1097/MOU.0000000000001305","url":null,"abstract":"Purpose of review: Biochemical recurrence (BCR) after radical prostatectomy exhibits heterogeneous prognostic implications. Recent advancements in imaging and biomarkers have high potential for personalizing care.Recent findings: Prostate-specific membrane antigen imaging (PSMA)-PET/CT has revolutionized the BCR management in prostate cancer by detecting microscopic lesions earlier than conventional staging, leading to improved cancer control outcomes and changes in treatment plans in approximately two-thirds of cases. Salvage radiotherapy, often combined with androgen deprivation therapy, remains the standard treatment for high-risk BCR postprostatectomy, with PSMA-PET/CT guiding treatment adjustments, such as the radiation field, and improving progression-free survival. Advancements in biomarkers, genomic classifiers, and artificial intelligence-based models have enhanced risk stratification and personalized treatment planning, resulting in both treatment intensification and de-escalation.Summary: While conventional risk grouping relying on Gleason score and PSA level and kinetics remain the foundation for BCR management, PSMA-PET/CT, novel biomarkers, and artificial intelligence may enable more personalized treatment strategies.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"522-526"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood- and urine-based biomarkers for the detection of clinically significant prostate cancer: a contemporary review. 基于血液和尿液的生物标志物检测临床意义重大的前列腺癌：当代回顾。

IF 2.2 3区医学

Current Opinion in Urology Pub Date : 2025-09-01 Epub Date: 2025-06-27 DOI: 10.1097/MOU.0000000000001308

Keavash D Assani, Janene M Pierce, Lan Anh Galloway, Jeffrey J Tosoian

{"title":"Blood- and urine-based biomarkers for the detection of clinically significant prostate cancer: a contemporary review.","authors":"Keavash D Assani, Janene M Pierce, Lan Anh Galloway, Jeffrey J Tosoian","doi":"10.1097/MOU.0000000000001308","DOIUrl":"10.1097/MOU.0000000000001308","url":null,"abstract":"Purpose of review: Prostate cancer (PCa) is the most common malignancy in men. While prostate-specific antigen (PSA) screening aids early detection, its low specificity leads to unnecessary biopsies and overdiagnosis of low-grade cancers. Blood- and urine-based biomarkers are proposed by clinical guidelines to better identify patients with elevated PSA that can safely avoid more intensive testing (e.g. imaging, biopsy). The current article aims to provide clinicians and researchers with a contemporary assessment of prostate cancer biomarker tests.Recent findings: This review focused on prebiopsy blood- and urine-based biomarker tests that are commercially-available and included in clinical guidelines. A systematic search identified 955 studies, of which 14 were published in the past 18 months (July 2023-January 2025) and reported performance metrics for clinically significant PCa (csPCa, defined as grade group ≥2). The literature revealed that blood- [Prostate Health Index (PHI), 4Kscore, and IsoPSA] and urine-based tests [SelectMDx, ExoDx IntelliScore (EPI), and MyProstateScore (MPS, MPS2)] maintained high sensitivity for csPCa while significantly reducing unnecessary biopsies performed relative to PSA-based testing. Furthermore, available data suggest that biomarkers can inform the need for biopsy in patients with equivocal (PI-RADS 3) mpMRI.Summary: Commercially-available, noninvasive biomarker tests consistently outperformed PSA and PSA-based risk calculators for detection of csPCa. Clinical use of these tests appears to substantially reduce the proportion of unnecessary biopsies performed, while maintaining detection of the vast majority of significant cancers.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"590-596"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in radiotherapy for genitourinary cancers. 泌尿生殖系统癌放射治疗的进展。

IF 2.2 3区医学

Current Opinion in Urology Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI: 10.1097/MOU.0000000000001320

Marcin Miszczyk

引用次数: 0

Does surgical removal of kidney stones help prevent the recurrence of urinary tract infections? A systematic review. 手术切除肾结石是否有助于预防尿路感染的复发？系统回顾。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-22 DOI: 10.1097/MOU.0000000000001328

Michelle Yuki Man, Bhaskar Somani, Amelia Pietropaolo

{"title":"Does surgical removal of kidney stones help prevent the recurrence of urinary tract infections? A systematic review.","authors":"Michelle Yuki Man, Bhaskar Somani, Amelia Pietropaolo","doi":"10.1097/MOU.0000000000001328","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001328","url":null,"abstract":"Purpose of review: Kidney stones disease (KSD) and urinary tract infections (UTIs) can be associated and reciprocally causal. Aim of this study is to understand the association between stone-free rate and infection clearance or recurrence after surgery.Recent findings: Studies are suggesting that removing stones may help to prevent UTIs. A systematic review was done to look at the relationship between UTIs and kidney stones and to find out whether stone removal surgery can help to reduce UTIs. The systematic review as done as per PRISMA checklist and three databases (Ovid MEDLINE, Cochrane Library and Embase) were searched for articles reporting on patients with recurrent UTIs and kidney stone surgery. All studies in English language were included with 1009 articles identified between 2000 and 2024.In the 10 studies finally selected, 1731 stones procedures were performed. Nine studies demonstrated a significant correlation between stone clearance and resolution of urinary tract infections.Summary: Surgical management of kidney stones appears to play a significant role in reducing UTI recurrence among patients with recurrent infections. Achieving stone clearance is associated with a higher likelihood of infection resolution and prolongation of infection-free intervals postoperatively.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Technological innovation and revolution with single-use digital flexible ureteroscopes: a review from section of EAU Endourology. 一次性数字化柔性输尿管镜的技术革新与革命：来自EAU输尿管学分会的综述。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-01-07 DOI: 10.1097/MOU.0000000000001260

Ali Talyshinskii, Lazaros Tzelves, Eugenio Ventimiglia, Steffi Kar Kai Yuen, Vineet Gauhar, Oliver Traxer, Bhaskar Somani

{"title":"Technological innovation and revolution with single-use digital flexible ureteroscopes: a review from section of EAU Endourology.","authors":"Ali Talyshinskii, Lazaros Tzelves, Eugenio Ventimiglia, Steffi Kar Kai Yuen, Vineet Gauhar, Oliver Traxer, Bhaskar Somani","doi":"10.1097/MOU.0000000000001260","DOIUrl":"10.1097/MOU.0000000000001260","url":null,"abstract":"Purpose of review: Numerous scope-related innovations have taken place in the field of endourology. The presented analytical review is aimed at studying the technical innovations of the single-use digital flexible ureteroscopes. In November 2024, a comprehensive search was done for information on latest disposable flexible digital ureteroscopes, as well as their various unique characteristics. A thorough examination was conducted for image qualities; sizes and channels; and deflection capabilities. Furthermore, supplementary features about the latest advances were assigned to a separate group including 'Unique' solutions. Using the last search query, various innovations in flexible ureteroscopy in general were also searched and sorted into appropriate groups.Recent findings: Modern single-use flexible digital ureteroscopes are characterized by advanced technologies for transmitting light and images, miniaturization, as well as by a number of unique solutions that were previously characteristic only of semi-rigid or fiberoptic endoscopes. These include features such as integrated buttons for data recording, self-locking mechanism, separate ports, rotating shaft, direct-in-scope suction, pressure monitoring, enhanced tip control and customizable settings.Summary: Since their introduction in urology, endoscopes have undergone many changes, as illustrated by the example of single-use flexible digital ureteroscopes. The imaging quality has improved, the dimensions of both the distal tip and shaft have decreased, with over 15 manufactures producing and distributing these scopes. A lot of new additional new features are likely to enhance the efficacy and safety of ureteroscopic procedures.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"360-367"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing clinical risk stratification of localized prostate cancer. 优化局限性前列腺癌的临床风险分层。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-05-02 DOI: 10.1097/MOU.0000000000001294

Vincent J Gnanapragasam

{"title":"Optimizing clinical risk stratification of localized prostate cancer.","authors":"Vincent J Gnanapragasam","doi":"10.1097/MOU.0000000000001294","DOIUrl":"10.1097/MOU.0000000000001294","url":null,"abstract":"Purpose of review: To review the current risk and prognostic stratification systems in localised prostate cancer. To explore some of the most promising adjuncts to clinical models and what the evidence has shown regarding their value.Recent findings: There are many new biomarker-based models seeking to improve, optimise or replace clinical models. There are promising data on the value of MRI, radiomics, genomic classifiers and most recently artificial intelligence tools in refining stratification. Despite the extensive literature however, there remains uncertainty on where in pathways they can provide the most benefit and whether a biomarker is most useful for prognosis or predictive use. Comparisons studies have also often overlooked the fact that clinical models have themselves evolved and the context of the baseline used in biomarker studies that have shown superiority have to be considered.Summary: For new biomarkers to be included in stratification models, well designed prospective clinical trials are needed. Until then, there needs to be caution in interpretation of their use for day-to-day decision making. It is critical that users balance any purported incremental value against the performance of the latest clinical classification and multivariate models especially as the latter are cost free and widely available.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"426-431"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measuring kidney stone volume - practical considerations and current evidence from the EAU endourology section. 测量肾结石体积-实际考虑和当前证据从EAU泌尿科。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-02-21 DOI: 10.1097/MOU.0000000000001271

Nico C Grossmann, Frederic Panthier, Luca Afferi, Panagiotis Kallidonis, Bhaskar K Somani

{"title":"Measuring kidney stone volume - practical considerations and current evidence from the EAU endourology section.","authors":"Nico C Grossmann, Frederic Panthier, Luca Afferi, Panagiotis Kallidonis, Bhaskar K Somani","doi":"10.1097/MOU.0000000000001271","DOIUrl":"10.1097/MOU.0000000000001271","url":null,"abstract":"Purpose of review: This narrative review provides an overview of the use, differences, and clinical impact of current methods for kidney stone volume assessment.Recent findings: The different approaches to volume measurement are based on noncontrast computed tomography (NCCT). While volume measurement using formulas is sufficient for smaller stones, it tends to overestimate volume for larger or irregularly shaped calculi. In contrast, software-based segmentation significantly improves accuracy and reproducibility, and artificial intelligence based volumetry additionally shows excellent agreement with reference standards while reducing observer variability and measurement time. Moreover, specific CT preparation protocols may further enhance image quality and thus improve measurement accuracy. Clinically, stone volume has proven to be a superior predictor of stone-related events during follow-up, spontaneous stone passage under conservative management, and stone-free rates after shockwave lithotripsy (SWL) and ureteroscopy (URS) compared to linear measurements.Summary: Although manual measurement remains practical, its accuracy diminishes for complex or larger stones. Software-based segmentation and volumetry offer higher precision and efficiency but require established standards and broader access to dedicated software for routine clinical use.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"323-330"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tissue-based gene expression testing in localized prostate cancer. 局部前列腺癌组织基因表达检测。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-05-02 DOI: 10.1097/MOU.0000000000001289

Nethusan Sivanesan, Gabriela M Diaz, Preston C Sprenkle

{"title":"Tissue-based gene expression testing in localized prostate cancer.","authors":"Nethusan Sivanesan, Gabriela M Diaz, Preston C Sprenkle","doi":"10.1097/MOU.0000000000001289","DOIUrl":"10.1097/MOU.0000000000001289","url":null,"abstract":"Purpose of review: This review presents the latest research in tissue-based genomic testing in localized prostate cancer (PCa). Here we explore the current and most commonly used genomic assays, their clinical applications, current challenges, and the future of genomic testing.Recent findings: The management of localized PCa has evolved with the integration of genomic assays, offering a more personalized approach to risk stratification and treatment decision-making. Traditional clinical markers such as PSA levels and Gleason scores are often insufficient in capturing clinically significant cancer due to disease heterogeneity.Summary: Tissue-based genomic tests, such as Decipher, Oncotype DX (GPS), and Prolaris, have emerged as prognostic tools for assessing tumor aggressiveness and metastatic potential. Current evidence supports Decipher's prognostic capabilities with studies demonstrating risk stratification while further research is needed for Prolaris and GPS to solidify their role in PCa risk stratification. These assays are intended to guide therapeutic choices, reducing overtreatment in low-risk cases while identifying high-risk patients who may benefit from more aggressive or definitive intervention. Despite growing clinical adoption, challenges such as cost, disparities in access, and variability in physician utilization still remain. Further prospective studies and randomized trials are required to optimize clinical implementation and validate the long-term impact of genomic testing on PCa outcomes.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"432-438"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0